Beyond their glucose-lowering capacity, SGLT2 inhibitors have recently been suggested to modulate lipid metabolism through mechanisms independent of glycemia, potentially improving or preventing dyslipidemia [10,11]. The gene discussed is SLC5A2; the disease is metabolic syndrome.